{"title":"EFFECTIVENESS AND TOLERABILITY OF APREMILAST IN TREATMENT OF A SAMPLE OF PATIENTS WITH PSORIASIS.","authors":"F Abdul-Reda, M Al-Zobaidy","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>Current study was aimed to appraise the effectiveness and tolerability of apremilast in psoriasis patients at AL-Diwaniyah province, Iraq.</p><p><strong>Materials and methods: </strong>This prospective cross-sectional study conducted at Dermatology Unit/ AL-Diwaniyah Teaching Hospital/ Iraq, during the period from January to October 2023. A total of 125 patients, 90 males and 35 females, were enrolled in this study. Patients who were eligible were treated for 6 months using apremilast at a dose of 30 mg/day. Psoriasis Area and Severity Index scoring system was used for assessment of patients' response to treatment. Data were analyzed using the Statistical Package for Social Sciences (version 26).</p><p><strong>Results: </strong>Data from current study revealed that there was a significant reduction of mean PASI score from 20.37±6.25 at baseline to 3.72±2.09 after 6 months of treatment (p<0.001).</p><p><strong>Conclusion: </strong>Apremilast is effective in reducing PASI mean score with negligible adverse effects. However, multi-center studies are needed to establish its efficacy and safety in Iraqi patients with psoriasis.</p>","PeriodicalId":12610,"journal":{"name":"Georgian medical news","volume":" 354","pages":"195-198"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Georgian medical news","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: Current study was aimed to appraise the effectiveness and tolerability of apremilast in psoriasis patients at AL-Diwaniyah province, Iraq.
Materials and methods: This prospective cross-sectional study conducted at Dermatology Unit/ AL-Diwaniyah Teaching Hospital/ Iraq, during the period from January to October 2023. A total of 125 patients, 90 males and 35 females, were enrolled in this study. Patients who were eligible were treated for 6 months using apremilast at a dose of 30 mg/day. Psoriasis Area and Severity Index scoring system was used for assessment of patients' response to treatment. Data were analyzed using the Statistical Package for Social Sciences (version 26).
Results: Data from current study revealed that there was a significant reduction of mean PASI score from 20.37±6.25 at baseline to 3.72±2.09 after 6 months of treatment (p<0.001).
Conclusion: Apremilast is effective in reducing PASI mean score with negligible adverse effects. However, multi-center studies are needed to establish its efficacy and safety in Iraqi patients with psoriasis.
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
